血管生成因子对足月生长相关新生儿疾病的预测评估及与竞争风险模型的比较
这项前瞻性观察研究在英格兰两家产科医院纳入29 035名孕妇,于孕35+0至36+6周检测血清PlGF和sFlt-1。竞争风险模型对足月生长相关新生儿疾病的预测优于高sFlt-1/PlGF比值或低PlGF。
要点
- 孕36周竞争风险模型预测生长相关新生儿疾病优于单用血管生成因子。
- sFlt-1/PlGF比值>38筛查阳性率13.1%,竞争风险模型检出率更高。
- PlGF<第10百分位筛查阳性率10.0%,竞争风险模型检出率显著更高。
核心结论
- 孕36周时,采用母体危险因素和估计胎儿体重的竞争风险模型对小于胎龄儿生长相关新生儿疾病的预测优于高sFlt-1/PlGF比值或低PlGF。
研究设计与样本
- 前瞻性观察研究,纳入英格兰两家产科医院孕35+0至36+6周常规产检孕妇29 035例,检测血清PlGF和sFlt-1。
主要发现
- 在筛查阳性率13.1%(sFlt-1/PlGF比值>38定义)下,竞争风险模型预测77.5%(95%CI 71.7-83.3%)的小于胎龄儿<第10百分位合并新生儿病房住院≥48小时,高于sFlt-1/PlGF比值>38的41.0%(95%CI 34.2-47.8%)(P<0.0001)。
- 在筛查阳性率13.1%下,竞争风险模型预测89.3%(95%CI 83.7-94.8%)的小于胎龄儿<第3百分位合并新生儿病房住院≥48小时,高于sFlt-1/PlGF比值>38的48.8%(95%CI 39.9-57.7%)(P<0.0001)。
- 在筛查阳性率10.0%(PlGF<第10百分位定义)下,竞争风险模型预测71.5%(95%CI 65.2-77.8%)的小于胎龄儿<第10百分位合并新生儿病房住院≥48小时,高于PlGF<第10百分位的36.5%(95%CI 29.8-43.2%)(P<0.0001)。
- 在筛查阳性率10.0%下,竞争风险模型预测84.3%(95%CI 77.8-90.8%)的小于胎龄儿<第3百分位合并新生儿病房住院≥48小时,高于PlGF<第10百分位的46.3%(95%CI 37.4-55.2%)(P<0.0001)。
关键数值与推荐
- 高sFlt-1/PlGF比值定义为>第90百分位或>38,低PlGF定义为<第10百分位。
- 主要结局为评估后4周内且孕<42周分娩的小于胎龄儿(出生体重<第10或<第3百分位)合并新生儿病房住院≥48小时或主要新生儿疾病复合结局。
临床怎么用
- 孕36周采用母体危险因素和估计胎儿体重的竞争风险模型预测生长相关新生儿疾病,优于单用高sFlt-1/PlGF比值或低PlGF。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: First, to describe the distribution of biomarkers of impaired placentation in small-for-gestational-age (SGA) pregnancies with neonatal morbidity; second, to examine the predictive performance for growth-related neonatal morbidity of a high soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio or low PlGF; and, third, to compare the performance of a high sFlt-1/PlGF ratio or low PlGF with that of the competing-risks model for SGA in predicting growth-related neonatal morbidity. METHODS: This was a prospective observational study of women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation in two maternity hospitals in England. The visit included recording of maternal demographic characteristics and medical history, an ultrasound scan and measurement of serum PlGF and sFlt-1. The primary outcome was delivery within 4 weeks after assessment and at < 42 weeks' gestation of a SGA neonate with birth weight < 10th or < 3rd percentile, combined with neonatal unit (NNU) admission for ≥ 48 h or a composite of major neonatal morbidity. The detection rates in screening by PlGF < 10th percentile, sFlt-1/PlGF ratio > 90th percentile, sFlt-1/PlGF ratio > 38 and the competing-risks model for SGA, using combinations of maternal risk factors and Z-scores of estimated fetal weight (EFW) with multiples of the median values of uterine artery pulsatility index, PlGF and sFlt-1, were estimated. The detection rates by the different methods of screening were compared using McNemar's test. RESULTS: In the study population of 29 035 women, prediction of growth-related neonatal morbidity at term provided by the competing-risks model was superior to that of screening by low PlGF concentration or a high sFlt-1/PlGF concentration ratio. For example, at a screen-positive rate (SPR) of 13.1%, as defined by the sFlt-1/PlGF ratio > 38, the competing-risks model using maternal risk factors and EFW predicted 77.5% (95% CI, 71.7-83.3%) of SGA < 10th percentile and 89.3% (95% CI, 83.7-94.8%) of SGA < 3rd percentile with NNU admission for ≥ 48 h delivered within 4 weeks after assessment. The respective values for SGA with major neonatal morbidity were 71.4% (95% CI, 56.5-86.4%) and 90.0% (95% CI, 76.9-100%). These were significantly higher than the respective values of 41.0% (95% CI, 34.2-47.8%) (P < 0.0001), 48.8% (95% CI, 39.9-57.7%) (P < 0.0001), 37.1% (95% CI, 21.1-53.2%) (P = 0.003) and 55.0% (95% CI, 33.2-76.8%) (P = 0.035) achieved by the application of the sFlt-1/PlGF ratio > 38. At a SPR of 10.0%, as defined by PlGF < 10th percentile, the competing-risks model using maternal factors and EFW predicted 71.5% (95% CI, 65.2-77.8%) of SGA < 10th percentile and 84.3% (95% CI, 77.8-90.8%) of SGA < 3rd percentile with NNU admission for ≥ 48 h delivered within 4 weeks after assessment. The respective values for SGA with major neonatal morbidity were 68.6% (95% CI, 53.1-83.9%) and 85.0% (95% CI, 69.4-100%). These were significantly higher than the respective values of 36.5% (95% CI, 29.8-43.2%) (P < 0.0001), 46.3% (95% CI, 37.4-55.2%) (P < 0.0001), 37.1% (95% CI, 21.1-53.2%) (P = 0.003) and 55.0% (95% CI, 33.2-76.8%) (P = 0.021) achieved by the application of PlGF < 10th percentile. CONCLUSION: At 36 weeks' gestation, the prediction of growth-related neonatal morbidity by the competing-risks model for SGA, using maternal risk factors and EFW, is superior to that of a high sFlt-1/PlGF ratio or low PlGF. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Papastefanou I, Nobile Recalde A, Silva Souza Y, et al. Evaluation of angiogenic factors in prediction of growth-related neonatal morbidity at term and comparison with competing-risks model. Ultrasound Obstet Gynecol. 2024. PMID: 37963283. doi:10.1002/uog.27533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。